NASDAQ:TRVI

Trevi Therapeutics Stock Forecast, Price & News

$2.23

-0.06 (-2.62 %)

(As of 06/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.20

▼

$2.33

50-Day Range

$2.00

▼

$2.70

52-Week Range

$1.94

▼

$8.50

Volume37,950 shs

Average Volume76,530 shs

Market Capitalization$44.44 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.08

30 days | 90 days | 365 days | Advanced Chart

Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Mexican pop star Gloria Trevi ate at San Antonio's Cuishe over the weekend
June 14, 2021 | msn.com

Trevi Therapeutics (NASDAQ:TRVI) & Cotinga Pharmaceuticals (OTCMKTS:COTQF) Head to Head Contrast
June 13, 2021 | americanbankingnews.com

Trevi Therapeutics to Present at 2021 BIO Digital Conference
June 9, 2021 | finance.yahoo.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 36.0% in May
May 31, 2021 | americanbankingnews.com

Gloria Trevi Renews Universal Music Latino Contract: Exclusive
April 8, 2021 | msn.com

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
April 7, 2021 | finance.yahoo.com

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
March 25, 2021 | finance.yahoo.com

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
March 19, 2021 | finance.yahoo.com

Gloria Trevi Dedicates Premio La Trayectoria Win to God & Family at Premio Lo Nuestro 2021
February 19, 2021 | msn.com

Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVI
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.trevitherapeutics.com
Phone203-304-2499
Employees23
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.48 per share
Price / Book1.51

Profitability

EPS (Most Recent Fiscal Year)($1.81)
Net Income$-32,760,000.00
Net MarginsN/A
Return on Equity-103.16%
Return on Assets-67.72%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares19,927,000
Market Cap$44.44 million
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.62 out of 5 stars

Medical Sector

430th out of 2,100 stocks

Pharmaceutical Preparations Industry

208th out of 832 stocks

3.4 Analyst's Opinion

Consensus Rating
Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Trevi Therapeutics has a forecasted upside of 393.3% from its current price of $2.23.
Amount of Analyst Coverage
Trevi Therapeutics has received no research coverage in the past 90 days.

2.2 Community Rank

Outperform Votes
Trevi Therapeutics has received 55 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Trevi Therapeutics has received 71 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Trevi Therapeutics has received 56.35% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote “Outperform” if you believe TRVI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Trevi Therapeutics does not currently pay a dividend.
Dividend Growth
Trevi Therapeutics does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
47.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
65.91% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($1.67) to ($3.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Trevi Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Trevi Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Trevi Therapeutics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

Is Trevi Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trevi Therapeutics stock.
View analyst ratings for Trevi Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Trevi Therapeutics?

Wall Street analysts have given Trevi Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevi Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a increase in short interest in May. As of May 14th, there was short interest totaling 83,900 shares, an increase of 36.0% from the April 29th total of 61,700 shares. Based on an average daily volume of 47,800 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.4% of the company's shares are sold short.
View Trevi Therapeutics' Short Interest.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Trevi Therapeutics.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, May, 13th. The company reported ($0.43) EPS for the quarter, beating the Zacks' consensus estimate of ($0.49) by $0.06.
View Trevi Therapeutics' earnings history.

How has Trevi Therapeutics' stock price been impacted by Coronavirus?

Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TRVI stock has decreased by 29.9% and is now trading at $2.23.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TRVI?

4 brokerages have issued 12 month target prices for Trevi Therapeutics' stock. Their forecasts range from $9.00 to $13.00. On average, they expect Trevi Therapeutics' stock price to reach $11.00 in the next year. This suggests a possible upside of 393.3% from the stock's current price.
View analysts' price targets for Trevi Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:

Ms. Jennifer L. Good, Co-Founder, CEO, Pres, Principal Financial Officer & Director (Age 56, Pay $662.64k)
Dr. Thomas R. Sciascia, Co-Founder & Chief Medical Officer (Age 68, Pay $476.25k)
Mr. Christopher Galletta, Controller & Chief Accounting Officer (Age 43)
Dr. Amale Hawi, Sr. VP of CMC (Age 67)
Mr. Frank P. Muscolo, Exec. Officer (Age 64)
Dr. William P. Forbes Pharm.D., Pharm. D., Chief Devel. Officer (Age 59)

Who are some of Trevi Therapeutics' key competitors?

Some companies that are related to Trevi Therapeutics include Anebulo Pharmaceuticals (ANEB), Heat Biologics (HTBX), Equillium (EQ), ObsEva (OBSV), Tyme Technologies (TYME), SELLAS Life Sciences Group (SLS), Actinium Pharmaceuticals (ATNM), PhaseBio Pharmaceuticals (PHAS), NeuBase Therapeutics (NBSE), Milestone Pharmaceuticals (MIST), Genprex (GNPX), Lantern Pharma (LTRN), Hepion Pharmaceuticals (HEPA), Eton Pharmaceuticals (ETON) and Abeona Therapeutics (ABEO).
View all of TRVI's competitors.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.61%), WealthTrust Axiom LLC (0.19%), BlackRock Inc. (0.16%), Citadel Advisors LLC (0.05%) and Citadel Advisors LLC (0.05%).
View institutional ownership trends for Trevi Therapeutics.

Which major investors are buying Trevi Therapeutics stock?

TRVI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, WealthTrust Axiom LLC, Citadel Advisors LLC, Citadel Advisors LLC, and BlackRock Inc..
View insider buying and selling activity for Trevi Therapeutics or or view top insider-buying stocks.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $2.23.

How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of $44.44 million. The company earns $-32,760,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Trevi Therapeutics have?

Trevi Therapeutics employs 23 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

Where are Trevi Therapeutics' headquarters?

Trevi Therapeutics is headquartered at 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]

This page was last updated on 6/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here